Affordable Access

Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer.

Authors
Type
Published Article
Journal
The Lancet Oncology
1470-2045
Publisher
Elsevier
Publication Date
Volume
2
Issue
6
Pages
335–342
Identifiers
PMID: 11905749
Source
Medline
License
Unknown

Abstract

The efficacy of radiotherapy in locally advanced non-small-cell lung cancer is limited. One attempt to improve survival uses a combination of radiation and chemotherapy. These two modalities can be applied in sequence or concurrently, but results from phase III trials of combined therapy versus radiation alone have been inconsistent. Early studies were mostly negative, but more recent trials using platinum-based regimens have shown some survival benefit for combined treatments. The positive impact of chemotherapy has also been shown in a meta-analysis. In recent studies, concurrent chemotherapy and radiation appears better than sequential application. However, the benefit of the combined approach is modest and should be balanced against increased early and late toxicity. The role of new agents such as taxanes, vinorelbine, gemcitabine, and topoisomerase inhibitors in combined modality therapy of non-small-cell lung cancer warrants further clinical investigation.

Statistics

Seen <100 times